FDA Warning Letters
The MHRA has reviewed its current approach to contacting UK Licence Holders who may be implicated by USFDA Warning Letters
Emerging issues – Communique from the GPhC
As part of maintaining professional vigilance and regulatory compliance across pharmacy services, PCL would like to draw attention to several critical issues recently highlighted by the General Pharmaceutical Council (GPhC).
New MHRA/NICE Collaboration
The UK is entering a new phase of innovation in how it regulates, assesses, and adopts new medicines—and it’s a development the global pharmaceutical and biopharmaceutical industry cannot afford to overlook.
The Future of Pharmacy first
Pharmacists, remember to direct their virtual patients to the Pharmacy First Survey to leave their feedback on the service.
Pharmaceutical Wholesalers – an eclectic bunch
It is probably true that there are no two pharmaceutical wholesales that are the same, but the variation out there is also probably a little surprising.
What are the main requirements for controlled drugs?
As described in the Misuse of Drugs Act 1971 and the Misuse of Drugs Regulations (MDR) 2001, any company wishing to possess, manufacture, produce or supply controlled drugs in England, Wales or Scotland will need to apply for a domestic licence – this includes where you are not physically handling but are directing and / or taking ownership.